{"id":37799,"date":"2018-11-15T08:59:42","date_gmt":"2018-11-15T06:59:42","guid":{"rendered":"http:\/\/infois.ro\/?p=37799"},"modified":"2018-11-15T09:00:03","modified_gmt":"2018-11-15T07:00:03","slug":"antibiotice-iasi-rezultate-economico-financiare-in-primele-9-luni-2018-majorare-cu-5-a-profitului-net-si-cu-3-a-veniturilor-din-vanzari","status":"publish","type":"post","link":"https:\/\/infois.ro\/?p=37799","title":{"rendered":"Antibiotice Ia\u0219i &#8211; rezultate economico-financiare \u00een primele 9 luni 2018: majorare cu 5% a profitului net \u0219i cu 3% a veniturilor din v\u00e2nz\u0103ri"},"content":{"rendered":"<p><a href=\"http:\/\/infois.ro\/wp-content\/uploads\/2014\/04\/antibiotice.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"alignleft wp-image-10892\" src=\"http:\/\/infois.ro\/wp-content\/uploads\/2014\/04\/antibiotice.jpg\" alt=\"\" width=\"420\" height=\"236\" srcset=\"https:\/\/infois.ro\/wp-content\/uploads\/2014\/04\/antibiotice.jpg 640w, https:\/\/infois.ro\/wp-content\/uploads\/2014\/04\/antibiotice-300x168.jpg 300w, https:\/\/infois.ro\/wp-content\/uploads\/2014\/04\/antibiotice-140x80.jpg 140w\" sizes=\"(max-width: 420px) 100vw, 420px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">\u00cen primele 9 luni ale anului 2018, compania Antibiotice a realizat un plus de 3% la veniturile din v\u00e2nz\u0103ri \u0219i un profit net \u00een cre\u0219tere cu 5% comparativ cu acela\u0219i interval din 2017. Din punct de vedere valoric, cei doi indicatori au atins nivelul de 241,25 milioane lei, respectiv 21,17 milioane lei, astfel ca rentabilitatea s-a men\u021binut la o cot\u0103 similar\u0103 cu cea \u00eenregistrat\u0103 anul trecut (8,8%).<\/p>\n<p style=\"text-align: justify;\">Cre\u0219terea veniturilor din v\u00e2nz\u0103ri se bazeaz\u0103 pe avansul de 5,3% ob\u021binut pe pia\u021ba intern\u0103, \u00a0ca urmare a evolu\u021biei favorabile pe clasele terapeutice cardiovascular, antiinfec\u021bioase \u0219i sistem nervos central. \u00cen ce prive\u0219te pia\u021ba interna\u021bional\u0103, veniturile din v\u00e2nz\u0103ri au r\u0103mas constante \u00een raport cu perioada precedent\u0103, cu o pondere de 37,8% din total v\u00e2nz\u0103ri. Cu toate acestea, au fost \u00eenregistrate cre\u0219teri \u00een zonele Asia (urmare volumului mai mare de produse finite livrate \u00een Vietnam), America Latina (prin dublarea v\u00e2nz\u0103rilor de Nistatin\u0103 \u00een Brazilia) \u0219i Orientul Mijlociu (gra\u021bie major\u0103rilor de la ambele categorii &#8211; produse finite \u0219i Nistatina).<\/p>\n<p style=\"text-align: justify;\">Pe l\u00e2ng\u0103 continuarea extinderii pe pie\u021bele interna\u021bionale \u2013 inclusiv prin \u00eenregistrarea a 29 de noi autoriza\u021bii de punere pe pia\u021b\u0103, compania a urm\u0103rit cre\u0219terea prezen\u021bei produselor Antibiotice \u00een farmaciile \u0219i spitalele din Rom\u00e2nia, respectiv completarea portofoliului cu produse noi \u0219i dezvoltarea activit\u0103\u021bilor \u0219tiin\u021bifice \u0219i de cercetare. Astfel, \u00een trimestrul III al anului 2018 Unitatea Clinic\u0103 a Centrului de Evaluare a Medicamentului a fost reautorizat\u0103 pentru desf\u0103\u0219urarea de studii clinice de bioechivalen\u021b\u0103 \u0219i faz\u0103 I.<\/p>\n<p style=\"text-align: justify;\">Potrivit strategiei de cre\u0219tere pe clase terapeutice, Antibiotice continu\u0103 investi\u021bia \u00een noua sec\u021bie de produse topice unde compania va produce un portofoliu complex \u00een urm\u0103torii ani.<a href=\"http:\/\/infois.ro\/wp-content\/uploads\/2014\/08\/antibiotice1.jpg\"><img loading=\"lazy\" decoding=\"async\" class=\"wp-image-12716 alignright\" src=\"http:\/\/infois.ro\/wp-content\/uploads\/2014\/08\/antibiotice1.jpg\" alt=\"\" width=\"332\" height=\"222\" srcset=\"https:\/\/infois.ro\/wp-content\/uploads\/2014\/08\/antibiotice1.jpg 600w, https:\/\/infois.ro\/wp-content\/uploads\/2014\/08\/antibiotice1-300x200.jpg 300w\" sizes=\"(max-width: 332px) 100vw, 332px\" \/><\/a><\/p>\n<p style=\"text-align: justify;\">Pentru planul de investi\u021bii propus pentru anul 2018 \u00een valoare de 116,3\u00a0milioane lei, compania a valorificat at\u00e2t resurse proprii c\u00e2t \u0219i credite bancare pe\u00a0termen scurt (linii de finan\u021bare) \u0219i pe termen lung. Sumele atrase au fost destinate at\u00e2t sus\u021binerii achizi\u021biilor prev\u0103zute \u00een planul de investi\u021bii c\u00e2t \u0219i achit\u0103rii taxei claw back (care a crescut cu 4,17 milioane lei) \u0219i a dividendelor c\u0103tre ac\u021bionari.<\/p>\n<p style=\"text-align: justify;\">\u00cen aceste condi\u021bii, gradul de \u00eendatorare a crescut fa\u021b\u0103 de aceea\u0219i perioad\u0103 a anului 2017 iar lichiditatea curent\u0103 s-a diminuat. Nivelul acestor indicatori se \u00eencadreaz\u0103 \u00een valorile planificate \u0219i \u00een limitele optime de siguran\u021b\u0103 \u0219i eficien\u021b\u0103 economic\u0103.<\/p>\n<p style=\"text-align: justify;\">Pe fondul cre\u0219terii produc\u021biei cu 22%, cheltuielile cu materiile prime \u0219i materialele consumabile au \u00eenregistrat un plus de 12%. Produc\u021bia suplimentar\u0103 a fost determinat\u0103 \u00een principal de nevoia cre\u0103rii unui stoc tampon de unguente \u0219i supozitoare care s\u0103 asigure continuitatea v\u00e2nz\u0103rilor \u00een perioada de transfer a fabrica\u021biei \u00een noua sec\u021bie de produse topice &#8211; obiectiv investi\u021bional \u00een curs. \u00cen plus, cheltuielile cu personalul au crescut cu 8%, ating\u00e2nd valoarea de 64,8 milioane lei, \u00een urma major\u0103rii salariale acordate \u00een 2017.<\/p>\n<p style=\"text-align: justify;\">Concluzii:<\/p>\n<ul>\n<li style=\"text-align: justify;\">venituri din v\u00e2nz\u0103ri \u00een cre\u0219tere cu 3% comparativ cu primele 9 luni ale anului 2017;<\/li>\n<li style=\"text-align: justify;\">profit net superior cu 5% comparativ cu aceea\u0219i perioad\u0103 a anului 2017;<\/li>\n<li style=\"text-align: justify;\">cre\u0219terea v\u00e2nz\u0103rilor din pia\u021ba intern\u0103 cu 5,3% comparativ cu perioada similar\u0103;<\/li>\n<li style=\"text-align: justify;\">cre\u0219terea veniturilor din v\u00e2nz\u0103ri realizate prin reprezentan\u021ba din Vietnam cu 35% \u0219i prin reprezentan\u021ba din Moldova cu 35%.<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>\u00cen primele 9 luni ale anului 2018, compania Antibiotice a realizat un plus de 3%&#8230; <a class=\"meta-more\" href=\"https:\/\/infois.ro\/?p=37799\">more <span class=\"meta-nav\">&raquo;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":10892,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[6,41],"tags":[74,279,40,11454,250,653,5651,7979],"aioseo_notices":[],"_links":{"self":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/37799"}],"collection":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=37799"}],"version-history":[{"count":1,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/37799\/revisions"}],"predecessor-version":[{"id":37800,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/posts\/37799\/revisions\/37800"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=\/wp\/v2\/media\/10892"}],"wp:attachment":[{"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=37799"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=37799"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/infois.ro\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=37799"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}